Related Experiment Video
Updated: Jun 1, 2026

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
Phase-ii evaluation of single-agent Carboplatin in advanced thyroid-carcinoma
S Ong1, L Degroot, N Vogelzang
1UNIV CHICAGO,DEPT MED,DIV BIOL SCI,HEMATOL ONCOL SECT,CHICAGO,IL 60637. UNIV CHICAGO,DEPT MED,DIV BIOL SCI,ENDOCRINOL SECT,CHICAGO,IL 60637.
Abstract:
Single agent carboplatin was used in a phase II trial to treat patients with metastatic thyroid cancer who had failed surgery, radiation therapy, or radioactive iodine. Carboplatin was administered at a dose of 400 mg/m(2) every 28 days on an outpatient basis. Eight patients with a variety of tumor histologies were enrolled. No patient had a response to treatment and the average time to disease progression while on treatment was 5.4 months. Toxicity was mild and included hearing loss in one patient. There have been few studies using newer agents in patients with metastatic thyroid cancer who failed surgery and radioactive iodine. These results underline the need for larger intergroup trials with newer agents.
More Related Videos
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...